Report : Asia Pacific Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology (Molecular Diagnostics {Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, Microarrays}, Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, and Microbiology), Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)
At 9.6% CAGR, the Asia Pacific Sepsis Diagnostics Market is speculated to be worth US$ 249.70 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific sepsis diagnostics market was valued at US$ 131.79 million in 2021 and is expected to reach US$ 249.70 million by 2028, registering a CAGR of 9.6% from 2021 to 2028. High incidence of sepsis due to increasing nosocomial infections are the critical factors attributed to the Asia Pacific sepsis diagnostics market expansion.
Infection is the root cause of sepsis. Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and chronic illnesses like diabetes. Among several types of infections, nosocomial infections are the primary cause of morbidity and mortality among hospitalized patients. Thus, the high incidence rate of sepsis is expected to boost the demand for sepsis diagnostic products, thereby supporting the Asia Pacific sepsis diagnostics market growth during the forecast period.
On the contrary, lack of skilled professionals hampers the Asia Pacific sepsis diagnostics market.
Based on product, the Asia Pacific sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held 43.7% share of Asia Pacific sepsis diagnostics market in 2021, amassing US$ 57.53 million. It is projected to garner US$ 108.19 million by 2028 to expand at 9.4% CAGR during 2021–2028.
Based on technology, the Asia Pacific sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held 44.3% share of Asia Pacific sepsis diagnostics market in 2021, amassing US$ 58.39 million. It is projected to garner US$ 108.74 million by 2028 to expand at 9.3% CAGR during 2021–2028.
Based on method, the Asia Pacific sepsis diagnostics market is segmented into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held 66.4% share of Asia Pacific sepsis diagnostics market in 2021, amassing US$ 87.51 million. It is projected to garner US$ 163.94 million by 2028 to expand at 9.4% CAGR during 2021–2028.
Based on test type, the Asia Pacific sepsis diagnostics market is segmented into point-of-care tests and laboratory tests. The laboratory tests segment held 84.6% share of Asia Pacific sepsis diagnostics market in 2021, amassing US$ 111.49 million. It is projected to garner US$ 210.34 million by 2028 to expand at 9.5% CAGR during 2021–2028.
Based on pathogen, the Asia Pacific sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held 79.6% share of Asia Pacific sepsis diagnostics market in 2021, amassing US$ 104.91 million. It is projected to garner US$ 201.64 million by 2028 to expand at 9.8% CAGR during 2021–2028.
Based on end user, the Asia Pacific sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others. The hospitals segment held 47.8% share of Asia Pacific sepsis diagnostics market in 2021, amassing US$ 63.04 million. It is projected to garner US$ 120.30 million by 2028 to expand at 9.7% CAGR during 2021–2028.
Based on country, the Asia Pacific sepsis diagnostics market has been categorized into the Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 35.9% share of Asia Pacific sepsis diagnostics market in 2021. It was assessed at US$ 47.35 million in 2021 and is likely to hit US$ 90.41 million by 2028, exhibiting a CAGR of 9.7% during the forecast period.
Key players dominating the Asia Pacific sepsis diagnostics market are Abbott; BD; bioMerieux SA; Danaher (Beckman Coulter); F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; Luminex Corporation; T2 Biosystems, Inc.; and THERMO FISHER SCIENTIFIC INC., among others.
- In Feb 2022; Abbott recalled several powdered infant formula products following reports of four infants developing bacterial infections after consuming the products. Three Cronobacter sakazakii infections and one Salmonella Newport infection was found among four infants in three states, namely, Minnesota, Ohio, and Texas. Cronobacter bacteria can cause severe, life-threatening infections (sepsis) or meningitis.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com